Drug Profile
Research programme: kidney disorder therapeutics - Amgen/Teijin Pharma
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Amgen; Teijin
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Kidney disorders
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Kidney disorders in Japan (unspecified route) (Amgen pipeline, September 2023)(Teijin Pharma pipeline, September 2023)
- 27 Sep 2023 Discontinued - Preclinical for Kidney disorders in USA (unspecified route) (Amgen pipeline, September 2023)(Teijin Pharma pipeline, September 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Kidney-disorders in Japan